EP2657246B1 - Modulator der aktivität von adenylatcyclase - Google Patents

Modulator der aktivität von adenylatcyclase Download PDF

Info

Publication number
EP2657246B1
EP2657246B1 EP11836112.0A EP11836112A EP2657246B1 EP 2657246 B1 EP2657246 B1 EP 2657246B1 EP 11836112 A EP11836112 A EP 11836112A EP 2657246 B1 EP2657246 B1 EP 2657246B1
Authority
EP
European Patent Office
Prior art keywords
compound
group
hydrogen atom
vidarabine
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP11836112.0A
Other languages
English (en)
French (fr)
Other versions
EP2657246A1 (de
EP2657246A4 (de
Inventor
Yoshihiro Ishikawa
Satoshi Okumura
Yujiro Hoshino
Seiichi Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yokohama National University NUC
Yokohama City University
Original Assignee
Yokohama National University NUC
Yokohama City University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yokohama National University NUC, Yokohama City University filed Critical Yokohama National University NUC
Publication of EP2657246A1 publication Critical patent/EP2657246A1/de
Publication of EP2657246A4 publication Critical patent/EP2657246A4/de
Application granted granted Critical
Publication of EP2657246B1 publication Critical patent/EP2657246B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/19—Purine radicals with arabinosyl as the saccharide radical

Definitions

  • the present invention relates to a modulator of adenylyl cyclase activity.
  • Heart failure is a major cause of death throughout the world. In Japan, heart failure is one of the three major causes of death.
  • a worldwide standard guideline for treating heart failure is to inhibit the chronically enhanced sympathetic nervous system activity in heart failure patients and renin-angiotensin system inhibitors and ⁇ -adrenoreceptor antagonists ( ⁇ -blockers) are used as main therapeutics.
  • ⁇ -blockers renin-angiotensin system inhibitors and ⁇ -adrenoreceptor antagonists
  • transient inhibition of cardiac function by ⁇ -blockers is a big obstacle to introduction of the treatment for patients, especially for aged patients.
  • ⁇ -blockers also have an inhibitory action on the respiratory tract and this causes a serious problem in aged patients who often have complications such as pulmonary emphysema.
  • ⁇ -adrenoreceptors modulate cardiac function by increasing the concentration of intracellular cyclic AMP (cAMP) through activation of adenylyl cyclase enzyme present in the cell membrane.
  • cAMP intracellular cyclic AMP
  • the above-mentioned ⁇ -blockers exert their pharmacological effects by inhibiting the activity of adenylyl cyclase enzyme and the downstream cAMP signals .
  • ⁇ -blockers cause bronchial smooth muscle contraction, which induces abnormalities in respiratory function.
  • ⁇ -blockers Such adverse effects of ⁇ -blockers on the respiratory system may be explained by the fact that having only 3 subtypes, ⁇ -adrenoreceptors are relatively low in the organ specificity of their expression.
  • adenylyl cyclase is known to have 9 subtypes and the subtypes called cardiac are expressed specifically in the heart but little in the lung.
  • ⁇ -blockers classified as agents of class II in Vaughan Williams classification have long been known to have an anti-arrhythmic action. Therefore, by selectively inhibiting cardiac adenylyl cyclase, therapeutic effects on heart failure and arrhythmia which are similar to the effects of ⁇ -blockers might be exerted without causing adverse effects on the respiratory tract.
  • Non-Patent Document No. 1 Some drugs targeting cardiac adenylyl cyclase have already been applied clinically.
  • Non-Patent Document No. 2 Although some compounds have already been reported as cardiac adenylyl cyclase inhibitors (Non-Patent Documents Nos. 2 and 3), neither clinical application has started nor novel compounds have been reported. Animal experiments performed to date have strongly suggested that cardiac adenylyl cyclase inhibitors are potentially useful as therapeutics for heart failure (Non-Patent Documents Nos. 4 to 7).
  • WO 95/18636 discloses hepatocyte - targeted drug conjugates which may include arabinofuranosyladenine derivatives.
  • the present inventors have synthesized a plurality of derivatives from vidarabine, a known inhibitor of cardiac adenylyl cyclase, and examined their inhibitory actions on cardiac adenylyl cyclase and their prophylactic effects on heart failure. With respect to prophylactic effect on heart failure, heart failure was actually produced in mouse models, which were then administered with cardiac adenylyl cyclase inhibitors and compared to study their therapeutic effects. As a result, the present inventors found novel compounds capable of inhibiting cardiac adenylyl cyclase, whereby the present invention has been achieved.
  • vidarabine Although vidarabine has an inhibitory effect on cardiac adenylyl cyclase, biodistribution of vidarabine shows extensive migration to central nervous system tissues because of its poor water solubility. For this reason, vidarabine may exhibit adverse effects on the central nervous system. Since the novel compound of the present invention has extremely high water solubility, its migration to the central nervous system is extremely small, indicating that it is believed that a high therapeutic effect on the heart can be obtained.
  • the novel compound of the present invention is effective as an inhibitor of the activity of cardiac adenylyl cyclase. It is possible to use the novel compound of the present invention as a therapeutic for diseases such as heart failure, myocardial infarction and arrhythmia.
  • R 1 , R 2 and R 3 each independently represent a hydrogen atom or a group represented by the following formula: B-(CH 2 ) n -CO- where n represents an integer from 1 to 4 and B is an amino group in which at least one hydrogen atom is substituted with an alkyl group, a carboxyl group or a hydroxycarbamoyl group, provided that all of R 1 , R 2 and R 3 are not simultaneously a hydrogen atom.
  • the compound of the present invention may occur as stereoisomers, and the present invention encompasses all of these stereoisomers.
  • optically active substances, diastereomers, racemates and the like are all included in the present invention.
  • the substituent represented by B may be an alkyl substituted amino group, a carboxyl group or a hydroxycarbamoyl group.
  • the alkyl group as a substitutent on the amino group is a C 1-4 straight- or branched-chain alkyl group.
  • Preferable alkyl groups include, but are not limited to, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group and tert-butyl group.
  • the compound of the present invention may be exemplified by compounds represented by any of the following formulas.
  • the compound of the present invention may be prepared according to the following reaction schemes.
  • disiloxanylidene-protected compound (III) was synthesized from vidarabine (II).
  • DCC dehydration-condensation agent
  • esterified compound (V) is obtained.
  • This esterified compound (V) is activated with 1-propylphosphoric acid cyclic anhydride and treated with hydroxylamine hydrochloride to thereby synthesize hydroxamic acid (VI).
  • treating (V) and (VI) separately with tetrabutylammonium fluoride to remove disiloxanylidene group position 2-substituted derivatives (Ib) and (Ic) of interest are obtained, respectively.
  • carboxylic acid with other acidic or basic group may be used and, instead of succinic anhydride, other carboxylic anhydride may be used.
  • silyl-protected compound (VII) was synthesized from vidarabine (II).
  • DCC dehydration-condensation agent
  • diester compound (XIII) was synthesized from vidarabine (II). By treating the compound (XIII) and N,N-dimethylglycine with a dehydration-condensation agent (DCC), it is possible to obtain triesterified compound (XIV) at a high yield.
  • DCC dehydration-condensation agent
  • pharmaceutically acceptable salts of the compound of the present invention include, but are not limited to, sodium phosphates, sodium salts, potassium salts, hydrochlorides and sulfates.
  • pharmaceutically acceptable esters of the compound of the present invention include, but are not limited to, ethylene glycol esters, diethylene glycol esters, triethylene glycol esters, polyethylene glycol esters and phosphates.
  • solvates of the compound of the present invention include, but are not limited to, solvates with water, methanol, ethanol, dimethylformamide and ethyl acetate.
  • the compound of the present invention or a pharmaceutically acceptable salt, ester or solvate thereof may be used as a modulator of adenylyl cyclase activity.
  • the compound of the present invention or a pharmaceutically acceptable salt, ester or solvate thereof may be used for prevention and/or treatment of indications for ⁇ -blockers (for example, heart failure, myocardial infarction, arrhythmia, angina, hypertension, and conditions and diseases associated therewith (such as tremor, motion sickness, jet lag, sleep disorder, Basedow's disease, gastroesophageal varices, migraine, Parkinson's disease, etc.)) ( Cardiac Practice 20, 69-73, 2009 ).
  • ⁇ -blockers for example, heart failure, myocardial infarction, arrhythmia, angina, hypertension, and conditions and diseases associated therewith (such as tremor, motion sickness, jet lag, sleep disorder, Basedow's disease, gastroesophageal varices, migraine, Parkinson's disease, etc.)
  • conditions and diseases associated with heart failure and/or myocardial infarction include, but are not limited to, arrhythmia, edema, shortness of breath, and angina.
  • the present invention provides a modulator of adenylyl cyclase activity, comprising the compound represented by the above-described formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof.
  • the drug of the present invention is especially effective on cardiac adenylyl cyclase.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound represented by the above-described formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof.
  • the compound or the like may be formulated into a pharmaceutical preparation (such as injection, capsule, tablet, powder or granule) according to conventional methods and then administered to a subject (human or animal).
  • a pharmaceutical preparation may be administered orally or parenterally at a daily dose of about 10-50 mg/kg body weight, preferably about 10-15 mg/kg body weight, as calculated for the amount of active ingredient.
  • This dose may be administered either at a time or in several divided portions.
  • the dose and frequency of administration may be appropriately changed depending on the symptoms and age of the patient, the administration route, and so forth.
  • a carrier such as distilled water or physiological saline may be used.
  • excipients such as starch, lactose, sucrose or calcium carbonate
  • binders such as starch paste, gum arabic, gelatin, sodium alginate, carboxymethylcellulose or hydroxypropylcellulose
  • lubricants such as magnesium stearate or talc
  • disintegrants such as starch, agar, microcrystalline cellulose, calcium carbonate, sodium hydrogencarbonate or sodium alginate may be used.
  • the content of the active ingredient in pharmaceutical preparations may be varied between 1 to 99% by weight.
  • the pharmaceutical preparation takes the form of tablets, capsules, granules or powder
  • the content of the active ingredient is preferably 5-80% by weight
  • the pharmaceutical preparation takes the form of injection
  • the content of the active ingredient is preferably 1-10% by weight.
  • the compound of the present invention or a pharmaceutically acceptable salt, ester or solvate thereof may also be used for antiaging and extending life span, for prevention of diseases and conditions associated therewith (for example, osteoporosis, aging such as wrinkles in the skin, excessive oxidative stress, hypofunction in organs, etc.) or for health maintenance.
  • the compound of the present invention or a pharmaceutically acceptable salt, ester or solvate thereof may be added to eatables and drinkables (for example, drinks such as sodas; foods such as candies, gum, bread; powdered products such as powder soup, fish flour); or may be combined with appropriate excipients, flavoring agents, coloring agents or the like, and formulated into pills, granules, tablets or capsules.
  • the resultant products may be supplied as health foods or dietary supplements.
  • the present invention provides a food composition comprising the compound of the present invention or a pharmaceutically acceptable salt, ester or solvate thereof.
  • the content of the compound of the present invention or a pharmaceutically acceptable salt, ester or solvate thereof in the food composition is preferably 0.1-50% by weight (as calculated for the amount of active ingredient).
  • adenylyl cyclase activity was lowered to about 20% of the activity level in wild type mice ( J. Biol. Chem. 278:16936-16940, 2003 ).
  • this tissue was believed to be appropriate for use in screening for drugs which selectively inhibit the activity of subtype 5.
  • the ultimate goal of the present study is to develop a new therapeutic for heart failure that is selective for type 5 adenylyl cyclase.
  • three vidarabine-based compounds were newly synthesized by imparting high levels of hydrophilicity. Further, the inhibitory effects of those compounds on type 5 were examined by the experiments described below. The inventors believe that the increased hydrophilicity contributes to inhibiting the irritancy that might be exerted on type 5 which is expressed in a part of the central nervous system (striatum).
  • Novel compounds having a dimethylamino acetate group introduced into positions 2, 3 and 5, respectively, of vidarabine were synthesized ( Fig. 1 ).
  • V2E position 2-substituted derivative
  • V3E position 3-substituted derivative
  • V5E position 5-substituted derivative
  • the resultant membrane preparations were incubated with a reaction mixture (20 mM HEPES, pH 8, 5 mM MgCl 2 , 0.5 mM EDTA, pH 8, 0.1 mM ATP, 1 mM phospho creatine, 8 U/mL creatine phosphor kinase, 200 ⁇ M IBMX) at 30°C in the presence of forskolin (an activator of adenylyl cyclase) (50 ⁇ M, Sigma Cat. No. F6886) and various compounds, to thereby allow production of cAMP.
  • striatum- or lung-derived membrane preparations were used in an amount of 1 ⁇ g
  • heart-derived membrane preparation was used in an amount of 2 ⁇ g.
  • Rat heart-derived H9c2 cells were cultured in 10% (v/v) fetal bovine serum (FBS)-containing Dulbecco's Modified Eagle Medium (DMEM, Sigma Cat. No. D6429) in the presence of 95% air + 5% CO 2 at 37°C. 80-90% confluent H9c2 cells were suspended in 10% FBS-containing DMEM. The cell suspension (500 ⁇ l) was added to each well of 24-well plates to give a density of 40,000 cells/well, and incubated overnight at 37°C. Subsequently, cells were incubated in serum-free DMEM (500 ⁇ l/well) for 48 hours and subjected to cAMP accumulation assay.
  • FBS fetal bovine serum
  • DMEM Dulbecco's Modified Eagle Medium
  • Sprague-Dawley male rats (Nippon SLC) (240-260 g) were anesthetized with pentobarbital (50 mg/kg ip). After administration of heparin (1000 UPS/kg iv), hearts were removed promptly, and swiftly mounted on a Langendorff apparatus. Perfusion was carried out with a calcium-free Tyrode solution containing 0.06% collagenase and 0.02% protease.
  • Cardiac myocytes liberated into KB solution (KOH 85 mM, KCl 30 mM, KE 2 PO 4 30mM, MgSO 4 3mM, EGTA 0.5mM, HEPES 10mM, 1-Glutamine 50mM, Taurin 20mM, pH 7.4) were filtered and suspended in 10% FBS-containing DMEM.
  • the cell suspension 500 ⁇ l was added to each well of 24-well plates to give a density of 40,000 cells/well, and incubated overnight at 37°C. Subsequently, cells were incubated in serum-free DMEM (500 ⁇ l/well) for 4 hours and subjected to cAMP accumulation assay ( Circulation 98, 1329-1334, 1998 ).
  • H9c2 cells were incubated in the presence of 500 ⁇ M IBMX for 20 minutes at 37 °C. Then, various vidarabine derivatives were added to the culture broth to give a concentration of 50 ⁇ M. Cells were further incubated for 10 minutes at 37 °C. Subsequently, forskolin was added thereto to give a concentration of 100 ⁇ M to thereby start cAMP production reaction. 20 minutes after the start of the reaction, culture broth was suctioned. 7.5% (v/v) TCA solution (200 ⁇ l) was added thereto to terminate the reaction. Cells were further incubated at 4 °C overnight. Similar experiments were also carried out on rat adult cultured cardiac myocytes under stimulation with various vidarabine derivatives (10 ⁇ M) and forskolin (5 ⁇ M).
  • the amount of cAMP contained in TCA solution was determined by radioimmunoassay using [ 125 I]-cAMP.
  • mice An osmotic mini-pump filled with isoproterenol was hypodermically implanted in mice, and isoproterenol was administered for 1 week continuously in a sustained-release manner (60 mg/kg).
  • the cardiac function of mice (EF, ejection fraction) was measured by cardiac ultrasonography, and values before and after isoproterenol administration were compared. It is generally known that when isoproterenol is administered to mice with a mini-pump, their cardiac function (EF) decreases (i.e., they manifest heart failure).
  • a culture broth of rat embryo cultured cardiac myocytes (pregnant Wistar rats were purchased from Nippon SLC) was stimulated (48 hours) with isoproterenol (10 -5 M) either alone or in combination with vidarabine, V2E, V3E or V5E (10 -5 M). Then, apoptosis positive cells were evaluated by TUNEL staining.
  • V2E, V3E and V5E were administered individually to WT (C57BL/6N; Nippon SLC) with an osmotic mini-pump (15 mg/kg/day for 7 days). Then, blood samples were taken and subjected to BUN, creatinine, GPT and GOT measurements. The results were compared with the results from control group.
  • Apoptosis positive cells of the mice used in the chronic catecholamine loading experiment were evaluated by TUNEL staining.
  • vidarabine derivatives ( Fig. 1 ) were dissolved in pure water to thereby prepare 10 mM stock solutions. Since vidarabine infusion of about 2 mM is used in clinical scenes as an antiherpes therapeutic (Arasena-A for intravenous infusion; Mochida Pharmaceutical Co., Ltd.), it was possible to prepare solutions at concentrations about 5 times higher than that of the infusion. In the present study, vidarabine was dissolved in 100% DMSO to prepare a 10 mM stock solution.
  • Adenylyl cyclase activity in the striatal membrane of WT increased about 15- to 20-fold as a result of stimulation with 50 ⁇ M forskolin.
  • vidarabine which had been reported as a type 5 selective inhibitor, inhibited adenylyl cyclase activity in the presence of forskolin up to about 17.3%.
  • V2E, V3E and V5E decreased the forskolin-stimulated adenylyl cyclase activity to about 24.5%, about 25.1 % and about 24.9%, respectively ( Fig. 2 ).
  • V2E inhibited adenylyl cyclase activity in wild-type mouse heart about 2.6 times as strong as in the lung and inhibited adenylyl cyclase activity in WT striatum about 3.0 times as strong as in the lung.
  • the tissue specificity of the inhibitory effect of vidarabine at said concentration is about 2.4-fold higher in the heart than in the lung and about 2.8-fold higher in the striatum than in the lung.
  • V2E is a highly hydrophilic compound having a type 5-selective inhibitory effect comparable to that of vidarabine ( Fig. 5 ).
  • Isoproterenol alone (60 mg/kg/day for 7 days) was administered to WT (C57BL/6N) for 1 week with an osmotic mini-pump (Alzet 2001).
  • Other WT received isoproterenol and, at the same time, vidarabine, V2E, V3E or V5E (15 mg/kg/day for 7 days).
  • vidarabine, V2E, V3E and V5E were dissolved or suspended in physiological saline and administered intraperitoneally 15 minutes before strychnine administration.
  • mice were inhalationally anesthetized with isoflurane, an electrode catheter (Millar: Model EPR800; size 1.1 F; length 4.5 cm) connected to an electrocardiogram amp for the purpose of recording intracardiac electrocardiogram was slowly inserted through the oral cavity into the esophagus, and fixed at a site where maximum P wave was recorded. The thus fixed electrode catheter was connected to an electrostimulator carefully enough to avoid any movment of its position. Thereafter, body surface electrogram was recorded by II lead. Subsequently, voltage stimuli of 2.5 mA were applied to mice for 60 seconds at intervals of 30 milliseconds to thereby induce transient atrial fibrillation. The time period during which the following phenomena can be confirmed from body surface electrogram was regarded as the duration of atrial fibrillation: P wave disappears from the baseline and the R-R intervals are not regular but produce arrhythmic pulse.
  • the present invention is applicable to prevention and/or treatment of diseases such as heart failure, myocardial infarction and arrhythmia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)

Claims (12)

  1. Verbindung der folgenden Formel (I') oder ein pharmazeutisch annehmbares bzw. annehmbarer Salz, Ester oder Solvat davon:
    Figure imgb0035
     worin R11, R12 und R13 jeweils unabhängig voneinander für ein Wasserstoffatom oder eine Gruppe der folgenden Formel stehen:

            B-(CH2)n-CO-

    wobei n für eine ganze Zahl von 1 bis 4 steht und B eine Aminogruppe ist, in der mindestens ein Wasserstoffatom ersetzt ist durch eine Alkylgruppe, eine Carboxylgruppe oder eine Hydroxycarbamoylgruppe, mit der Maßgabe, dass nicht alle von R11, R12 und R13 gleichzeitig ein Wasserstoffatom sind und mit der Maßgabe, dass die Verbindung nicht 5'-O-(3-Carboxypropionyl)-9-β-D-arabinofuranosyladenin oder 5'-O-(4-Carboxybutyryl)-9-β-D-arabinofuranosyladenin ist.
  2. Verbindung nach Anspruch 1, welche dargestellt wird durch eine der folgenden Formeln:
    Figure imgb0036
    Figure imgb0037
    Figure imgb0038
    Figure imgb0039
    Figure imgb0040
    Figure imgb0041
    Figure imgb0042
  3. Verbindung nach Anspruch 1 oder 2 zur Verwendung in einem Verfahren zur Prävention und/oder Behandlung einer Indikation für β-Blocker.
  4. Pharmazeutische Zusammensetzung, umfassend die Verbindung nach Anspruch 1, 2 oder 3 oder ein(en) pharmazeutisch annehmbares bzw. annehmbaren Salz, Ester oder Solvat davon.
  5. Nahrungsmittelzusammensetzung, umfassend die Verbindung nach Anspruch 1 oder 2 oder ein(en) pharmazeutisch annehmbares bzw. annehmbaren Salz, Ester oder Solvat davon.
  6. Nahrungsmittelzusammensetzung nach Anspruch 5 zur Verwendung zur Prävention von Erkrankungen und Zuständen, die assoziiert sind mit Antiaging und Ausdehnung der Lebensdauer, oder zur Verwendung in der Gesundheitserhaltung.
  7. Verbindung der folgenden Formel (I') oder ein pharmazeutisch annehmbares bzw. annehmbarer Salz, Ester oder Solvat davon zur Verwendung in einem Verfahren der auf den menschlichen oder tierischen Körper angewandten Therapie,
    Figure imgb0043
     wobei R11, R12 und R13 jeweils unabhängig voneinander ein Wasserstoffatom oder für eine Gruppe der folgenden Formel stehen:

            B-(CH2)n-CO-

    wobei n für eine ganze Zahl von 1 bis 4 steht und B eine Aminogruppe ist, in der mindestens ein Wasserstoffatom ersetzt ist durch eine Alkylgruppe, eine Carboxylgruppe oder eine Hydroxycarbamoylgruppe, mit der Maßgabe, dass nicht alle von R11, R12 und R13 gleichzeitig ein Wasserstoffatom sind.
  8. Verbindung zur Verwendung nach Anspruch 7 oder zur Verwendung in einem Verfahren der Prävention und/oder Behandlung einer Indikation für β-blocker.
  9. Verbindung zur Verwendung nach Anspruch 8, wobei die Indikation für β-blocker ausgewählt ist aus der Gruppe, bestehend aus Herzversagen, Myokardinfarkt, Arrhythmie, Angina, Bluthochdruck und Zuständen und Erkrankungen, die damit assoziiert sind.
  10. Verwendung einer Verbindung der folgenden Formel (I') oder eines pharmazeutisch annehmbaren Salzes, Esters oder Solvats davon zur Herstellung eines Medikaments zur Prävention und/oder Behandlung einer Indikation für β-blocker:
    Figure imgb0044
     worin R11, R12 und R13 jeweils unabhängig voneinander für ein Wasserstoffatom oder eine Gruppe der folgenden Formel stehen:

            B-(CH2)n-CO-

    wobei n für eine ganze Zahl von 1 bis 4 steht und B eine Aminogruppe ist, in der mindestens ein Wasserstoffatom ersetzt ist durch eine Alkylgruppe, eine Carboxylgruppe oder eine Hydroxycarbamoylgruppe, mit der Maßgabe, dass nicht alle von R11, R12 und R13 gleichzeitig ein Wasserstoffatom sind und mit der Maßgabe, dass die Verbindung nicht 5'-O-(3-Carboxypropionyl)-9-β-D-arabinofuranosyladenin oder 5'-O-(4-Carboxybutyryl)-9-β-D-arabinofuranosyladenin ist.
  11. Pharmazeutische Zusammensetzung zur Verwendung in einem Verfahren zur auf den menschlichen oder tierischen Körper angewandten Therapie, umfassend eine Verbindung der folgenden Formel (I') oder ein(en) pharmazeutisch annehmbares bzw. annehmbaren Salz, Ester oder Solvat davon:
    Figure imgb0045
     wobei R11, R12 und R13 jeweils unabhängig voneinander ein Wasserstoffatom oder für eine Gruppe der folgenden Formel stehen:

            B-(CH2)n-CO-

    wobei n für eine ganze Zahl von 1 bis 4 steht und B eine Aminogruppe ist, in der mindestens ein Wasserstoffatom ersetzt ist durch eine Alkylgruppe, eine Carboxylgruppe oder eine Hydroxycarbamoylgruppe, mit der Maßgabe, dass nicht alle von R11, R12 und R13 gleichzeitig ein Wasserstoffatom sind.
  12. Pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 11 zur Verwendung bei der Prävention und/oder Behandlung einer Indikation für β-blocker.
EP11836112.0A 2010-10-27 2011-10-20 Modulator der aktivität von adenylatcyclase Not-in-force EP2657246B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010240301 2010-10-27
PCT/JP2011/074098 WO2012056976A1 (ja) 2010-10-27 2011-10-20 アデニル酸シクラーゼの活性調節剤

Publications (3)

Publication Number Publication Date
EP2657246A1 EP2657246A1 (de) 2013-10-30
EP2657246A4 EP2657246A4 (de) 2014-04-02
EP2657246B1 true EP2657246B1 (de) 2016-04-13

Family

ID=45993689

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11836112.0A Not-in-force EP2657246B1 (de) 2010-10-27 2011-10-20 Modulator der aktivität von adenylatcyclase

Country Status (4)

Country Link
US (1) US9096632B2 (de)
EP (1) EP2657246B1 (de)
JP (1) JP5849336B2 (de)
WO (1) WO2012056976A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3936118B2 (ja) * 2000-03-28 2007-06-27 昭和医科工業株式会社 ロッドグリッパー
WO2013051330A1 (ja) * 2011-10-07 2013-04-11 公立大学法人横浜市立大学 ビダラビンによる心房細動治療
CZ308881B6 (cs) * 2014-12-09 2021-08-04 Univerzita Palackého v Olomouci 6-aryl-9-glykosylpuriny a jejich použití

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1679195A (en) 1994-01-11 1995-08-01 Targetech, Incorporated, A Wholly Owned Subsidiary Of The Immune Response Corporation Hepatocyte-targeted drug conjugates
JP2000302675A (ja) 1999-04-19 2000-10-31 Sankyo Co Ltd 塩基性化合物を含有する医薬
US20070167353A1 (en) 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
CN100519536C (zh) 2006-03-21 2009-07-29 中国医学科学院医药生物技术研究所 一组连有核苷碱基的格尔德霉素衍生物
JP2010240301A (ja) 2009-04-09 2010-10-28 Kgf Japan:Kk 葬儀方法

Also Published As

Publication number Publication date
WO2012056976A1 (ja) 2012-05-03
JP5849336B2 (ja) 2016-01-27
US9096632B2 (en) 2015-08-04
US20130261073A1 (en) 2013-10-03
JPWO2012056976A1 (ja) 2014-05-12
EP2657246A1 (de) 2013-10-30
EP2657246A4 (de) 2014-04-02

Similar Documents

Publication Publication Date Title
CN106822168B (zh) 含硒有机化合物的组合物和其使用方法
US20240166680A1 (en) Nucleoside analog and use thereof
EP2725018B1 (de) Substituiertes cinnamamidderivat, herstellungsverfahren dafür und verwendung davon
HU230066B1 (hu) Mitokondriális betegségek kezelésére szolgáló eljárások és készítmények
US20110166093A1 (en) Use of adenosine receptor agonists in therapy
BR112015001211B1 (pt) Ácidos 5-aminotetra-hidroquinolina-2-carboxílicos, processos para a sua preparação, seus usos no tratamento e/ou prevenção de doenças e seus medicamentos
US20080075666A1 (en) Methods and compositions for treating diastolic dysfunction
EP3313816B1 (de) Metabolisch robuste analoga von cyp-eicosanoiden zur behandlung von herzkrankheiten
EP2657246B1 (de) Modulator der aktivität von adenylatcyclase
RU2730512C2 (ru) Новые производные CYP-эйкозаноидов
KR20210023984A (ko) 헤테로환형 고리 및 아미노기로 치환된 피리딘 유도체
JP5777011B2 (ja) コルホルシンダロパートを含む骨疾患の予防または治療用組成物
JP2013545809A (ja) 骨格筋および皮膚の成長、修復、および維持を促進するようにブラシノステロイドを産生および使用する方法
EP3984993A1 (de) Verwendung von aminothiolverbindungen als hirnnerven- oder herzschutzmittel
EP3906969A1 (de) Antihypertensive polyolverbindung und derivat davon
EP2554165A1 (de) Prophylaktischer oder therapeutischer wirkstoff gegen diabetes oder adipositas
KR102265708B1 (ko) 아미노산 유도체, 이의 제조방법 및 이를 포함하는 b형 간염 또는 d형 간염 치료용 약학적 조성물
EP3050871A1 (de) Neuartige bisamidderivate und verwendung davon
CN114466855A (zh) 用于治疗心力衰竭的具有作为SERCA2a的纯或显著纯刺激剂活性的雄甾烷衍生物
AU2019312478B2 (en) 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
CN110066258A (zh) 噻唑-5-甲酸衍生物及其制备方法与应用
EP1532140A1 (de) Thienylhydrazone mit digitalis-analogen eigenschaften ( positiv inotroper effekt )
EP3299373A2 (de) Medicarpin, derivate davon, herstellungsverfahren dafür
KR20130091604A (ko) 시난디온 ａ를 포함하는 항염증용 조성물
HUT75093A (en) New anti-radical pharmaceutical compositions and process for producing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140228

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/06 20060101ALI20140224BHEP

Ipc: A61P 9/00 20060101ALI20140224BHEP

Ipc: A61P 9/10 20060101ALI20140224BHEP

Ipc: C07H 19/19 20060101AFI20140224BHEP

Ipc: A61P 9/12 20060101ALI20140224BHEP

Ipc: A61P 9/04 20060101ALI20140224BHEP

Ipc: A61K 31/7076 20060101ALI20140224BHEP

Ipc: A61P 43/00 20060101ALI20140224BHEP

Ipc: A61P 1/08 20060101ALI20140224BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20151029

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HOSHINO, YUJIRO

Inventor name: INOUE SEIICHI

Inventor name: OKUMURA, SATOSHI

Inventor name: ISHIKAWA, YOSHIHIRO

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 790033

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160415

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011025383

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 790033

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160413

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160714

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011025383

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

26N No opposition filed

Effective date: 20170116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161102

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20111020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181009

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20181017

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602011025383

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200501

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20191020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191020